Bibliographic Details
| Title: |
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. |
| Authors: |
Shepard DR; Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue/Desk R35, Cleveland, OH 44195, USA. shepard@ccf.org, Cooney MM, Elson P, Bukowski RM, Dreicer R, Rini BI, Garcia JA |
| Source: |
Investigational new drugs [Invest New Drugs] 2012 Feb; Vol. 30 (1), pp. 364-7. Date of Electronic Publication: 2010 Aug 14. |
| Publication Type: |
Clinical Trial, Phase II; Journal Article |
| Journal Info: |
Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
